Types & Combinations
|
Abstracts & Links
|
Rituxan (Rituximab)
Treatment of cd20 positive b-cell lymphomas
|
See Details FDA approved
Both normal and malignant cells express CD20. However, because precursor b-cells do not, normal b-cells will return ~6 mo. after treatment.
|
Rituxan Combinations
The goal of combining combining antibodies, biologic or chemotherapy agents with Rituxan is to improve the response rate, and the duration of response.
Other Combinations
.gif) |
Viragen Antibody Enhances Effect of Leading Cancer Drug prnewswire | bloodjournal.org
In Vitro study shows benefit of anti-CD55 antibody and Rituxan®
|
|
Preclinical: Fully human anti-MHC class II monoclonal antibody, 1D09C3, may have potent synergistic activity with Rituxan press release
|
|
Dipeptidyl peptidase inhibitor and Rituxan (PT-100) ASCO
|
|
Rituxan + chemotherapy
For CD20 positive b-cell indolent, transformed or aggressive lymphomas
|
Abstracts & Links
-
Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma. Expert Rev Anticancer Ther. 2001 Aug;1(2):177-86. Review.
PMID: 12113023 PubMed
-
Immunochemotherapy in indolent non-Hodgkin's lymphoma.
Semin Oncol. 2002 Apr;29(2 Suppl 6):11-7. Review.
PMID: 12040529 PubMed
|
Rituxan + CpG 7909
CpG is a biological response modifier.
|
"... immunostimulatory CpG ODN can enhance antibody dependent cellular cytotoxicity and warrant further evaluation as potential immunotherapeutic reagents in cancer."[1]
Abstracts & Links
-
Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood. 1997 Apr 15;89(8):2994-8. PMID: 9108420
|
Rituxan + GM-CSF (Leukine)
GM-CSF stands for Granulocyte -Macrophage Colony-Stimulating Factor. It's a biologic that stimulates immunity, and possibly the expression of CD20 on B-cells.
|
Abstracts & Links
-
Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of rituxan and G-CSF: final report on safety and efficacy. Leukemia. 2003 Aug;17(8):1658-1664. PMID: 12886256 PubMed | Related abstracts
-
Effect of GM-CSF, G-CSF or Methylprednisolone (MP) on Rituximab-Associated Complement-Mediated Cytotoxicity (CMC) on Non-Hodgkin’s Lymphoma (NHL) Cell Lines ASCO 2001 # 1095
-
Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies. J Immunol Methods. 2001 Feb 1;248(1-2):103-11. PMID: 11223072 PubMed
-
Beyond immunochemotherapy: combinations of rituximab with cytokines interferon-alpha2a and granulocyte-macrophage colony stimulating factor. Semin Oncol. 2002 Apr;29(2 Suppl 6):7-10. Review. PMID: 12040528 PubMed
|
Rituxan + Epratuzumab
Epratuzumab targets the CD22 antibody on B-cells
|
Abstracts & Links
-
Epratuzumab (anti-CD22) and rituximab (anti-CD20) combination immunotherapy for non-Hodgkin's lymphoma: preliminary response data Year: 2002 Abstract No: 1060
-
Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). Semin Oncol. 2002 Feb;29(1 Suppl 2):81-6. Review. PMID: 11842393 PubMed
|
Rituxan + Galiximab (anti-cd80)
|
-
A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with Rituxan for relapsed or refractory, follicular lymphoma. Ann Oncol. 2007 Jul;18(7):1216-23. Epub 2007 Apr 29. PMID: 17470451
73 patients received treatment. All had received at least one prior lymphoma therapy; 40% were rituximab naive. Infusions were delivered in an outpatient setting and were well tolerated. The most common study-related adverse events (AE) were lymphopenia, leukopenia, neutropenia, fatigue, and chills. The overall response rate at the recommended phase II dose of galiximab (500 mg/m(2)) was 66%: 19% complete response, 14% unconfirmed complete response, and 33% partial response. The median progression free survival was 12.1 months.
|
Rituxan + interferon-alpha2a (IFN)
INF-alpha is a biological response modifier.
NOTE: The pegylated version might reduce side effects and provide more consistent dosing.
|
Abstracts & Links
-
Beyond immunochemotherapy: combinations of rituximab with cytokines interferon-alpha2a and granulocyte-macrophage colony stimulating factor. Semin Oncol. 2002 Apr;29(2 Suppl 6):7-10. Review.
PMID: 12040528 PubMed
-
Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. Haematologica. 2001 Sep;86(9):951-8. PMID: 11532623 PubMed
-
Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a.
Clin Cancer Res. 2000 Jul;6(7):2644-52. PMID: 10914705 PubMed
|
Rituxan + Interleukin-2 (IL-2)
IL-2, a cytokine, is a biological response modifier. (Proleukin®)
NOTE: The pegylated version might reduce side effects and provide more consistent dosing.
|
Abstracts & Links
-
Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma.
Br J Haematol. 2002 Jun;117(4):828-34. PMID: 12060117 PubMed
-
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer ClinicalTrials.gov
|
Rituxan + Interleukin-11 (IL-11)
IL-11, a cytokine, is a biological response modifier.
|
Abstracts & Links
-
Monoclonal Antibody Therapy Plus Sargramostim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma ClinicalTrials.gov
|
Rituxan + Interleukin-12 (IL-12)
IL-12, a cytokine, is a biological response modifier.
|
Abstracts & Links
-
Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol. 2002 Jun;117(4):828-34. PMID: 12060117 PubMed
|
| Rituxan + Revlimid (Lenaliomide) |
Study: Rituxan and/or Lenalidomide (Revlimid)
Condition: follicular lymphoma - relapsed following Rituxan-based combination therapy
Rationale and goal: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them.
Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Lenalidomide may also stop the growth of non-Hodgkin's lymphoma by blocking blood flow to the cancer. Giving rituximab together with lenalidomide may kill more cancer cells.
 TOPIC SEARCH: Mechanisms PubMed
Outcome ASCO | Medscape | PubMed
Safety ASCO | PubMed
|
Other Antibodies for B- and T- Cell Lymphomas
|
Anti-cd69
Preclinical (early)
|
"The leukocyte activation marker CD69 is a novel regulator of the immune response, modulating the production of cytokines including transforming growth factor-beta (TGF-beta)." PMID: 15692061
Abstracts and Resources
-
Induction of tumor NK-cell immunity by anti-CD69 antibody therapy. Blood. 2005 Jun 1;105(11):4399-406. Epub 2005 Feb 3. PMID: 15692061
|
Campath (alemtuzumab)
For CD52 positive B- and T-cell lymphomas
Conditions: Small cell lymphocytic non-Hodgkin's lymphomas (NHL) of B- and T-cell type
|
"A humanized monoclonal antibody directed against the CD52 antigen with promising therapeutic effects in patients with small cell lymphocytic non-Hodgkin's lymphomas (NHL) of B- and T-cell type." [1]
Abstracts & Resources
Related PubMed Abstracts
-
Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study. Ann Hematol. 2002 Jan;81(1):26-32. PMID: 11807632 PubMed
-
Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Leuk Lymphoma. 2002 May;43(5):1007-11.
PMID: 12148879 PubMed
-
Alemtuzumab in T-cell malignancies.
Med Oncol. 2002;19 Suppl:S27-32. PMID: 12180489 PubMed
-
About FDA.gov
-
Phase II study of alemtuzumab in chronic lymphoproliferative disorders.
Cancer. 2003 Aug 15;98(4):773-8. PMID: 12910522 | Abstracts
-
Campath - alone or combined with Rituxan for refractory CLL mdanderson.org
-
Campath data for CLL abstracts
|
CT-011 antibody
targets B7 family-associated protein, |
ClinicalTrials.gov
Indication: Lymphomas
|
hA20
Humanized anti-CD20 antibody
|
Clinical Trials
"According to Dr. Morschhauser, "These results with hA20 compare favorably to a published report of a similar patient population retreated with rituximab after at least one prior course of this antibody, where overall and complete response rates of 40% and 11%, respectively, were observed for the usual dose of 375 mg/m(2) weekly for four weeks (TA Davis et al., J Clin Oncol 2000; 18:3135-43).
Throughout the doses studied with hA20, an encouragingly high complete response rate, averaging 22%, and durable responses at each dose level were observed in these low-grade or follicular lymphoma patients."
|
HUMAX-CD4
For CD4 positive T-cell NHL
|
Genmab's Enmab’S HUMAX-CD4 to be Tested in Cancer Patients
HuMax-CD4® is a high-affinity, fully human antibody that targets the CD4 receptor on T-cells and is currently in development for cutaneous T-cell lymphoma (CTCL) and non-cutaneous T-cell lymphoma (NCTCL). HuMax-CD4 has been designated a Fast Track Product by the US Food and Drug Administration (FDA), covering patients with CTCL who have failed currently available therapy. HuMax-CD4 has also been granted Orphan Drug status in the US, Europe and Australia for the treatment of CTCL and for the treatment of NCTCL in Europe. GENMAB
|
HuMax-CD4(TM) Continues to Show Long Lasting Responses in T-Cell Lymphoma Patients prnewswire.com
|
|
Ofatumumab cd20
(approved for refractory CLL)
For CD20 positive B-cell NHL
|
|
2012 - Ofatumumab - Chemoimmunotherapy with Ofatumumab in combination with CHOP in previously untreated follicular lymphoma onlinelibrary.wiley.com/ |
"HuMax-CD20® is a fully human, high-affinity antibody targeted at the CD20 molecule in the cell membrane of B-cells ..... HuMax-CD20 is in clinical development for the treatment of non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA) and diffuse large B-cell lymphoma (DLBCL). HuMax-CD20 has been designated a Fast Track Product by the FDA covering patients with CLL who have failed fludarabine therapy, including those who are refractory to available treatment. Genmab and GSK have announced details of a planned Phase II study in remitting relapsing multiple sclerosis (RRMS), expected to begin in 2008. In addition, randomized Phase III studies in CLL and follicular NHL are being planned. Other potential indications for HuMax-CD20 include Crohn's disease, Wegener's Granulomatosis, other B-cell lymphomas, including mantle cell lymphoma and autoimmune disease.." genmab.com
|
Bispecific antibodies (BsAb) BiTE
For CD19 positive B-cell NHL
Conditions: NHL
Animations
What is a BiTE™s?
micromet
How does it work?
micromet
|
"Bispecific monoclonal antibodies, with a dual specificity for tumor associated antigens on target cells and for surface markers on immune effector cells, have been shown (in vitro) to be effective in directing and triggering effector cells to kill target cells resulting in target cell lysis." [1]
Clinical Trials of Bispecific Antibodies
TOPIC SEARCH: Mechanisms PubMed
Abstracts & Links
Related PubMed Abstracts
-
Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy. Leuk Lymphoma. 1995 Nov;19(5-6):381-93. Review.
PMID: 8590837 PubMed
-
Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer. 2002 Aug 20;100(6):690-7. PMID: 12209608 PubMed
-
The Bi-Specific T-Cell Enhancer (BiTE) MT103 (MEDI-538) Induces Clinical Responses in Heavily Pre-Treated NHL Patients: Update from the Ongoing Phase I Study MT103-104. ASH 2006
|
BL22
For CD22 positive B-cell lymphomas
BL22 recombinant immunotoxin BL22
Conditions: NHL
|
A toxin fused to an antibody that seeks and binds to receptors on lymphoma cells (Recombinant immunotoxins for the treatment of haematological malignancies)
Abstracts & Links
-
Encouraging report on use of BL22 for Hairy cell Leukemia cancerconsultants
-
Recombinant immunotoxins for the treatment of haematological malignancies. Expert Opin Biol Ther. 2004 Jul;4(7):1115-28. PMID: 15268678
-
Technology evaluation: BL22, NCI. Curr Opin Mol Ther. 2002 Feb;4(1):72-5. PMID: 11883697 PubMed
|
Eprituzamab (hLL2)
For CD22 positive B-cell NHL
Conditions: NHL
|
Current clinical investigations with humanized anti-CD22 includes as a treatment as single agent, in combination with Rituxan, and a radiolabeled version.
Abstracts & Links
Related PubMed Abstracts
-
131I-labelled anti-CD22 MAb (LL2) in patients with B-cell lymphomas failing chemotherapy. Treatment outcome, haematological toxicity and bone marrow absorbed dose estimates. Acta Oncol. 2002;41(3):297-303.
PMID: 12195750 PubMed
-
Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: a new generation of therapeutics.
Leuk Lymphoma. 2002 May;43(5):953-9. PMID: 12148905 PubMed
-
Epratuzumab (anti-CD22) and rituximab (anti-CD20) combination immunotherapy for non-Hodgkin's lymphoma: preliminary response data Year: 2002 Abstract No: 1060
|
brentuximab vedotin
|
approved for Hodgkins lymphoma
FDA Briefing Document
Oncologic Drugs Advisory Committee Meeting
July 14, 2011 | BLA 125388
(Adcetris) brentuximab vedotin
Proposed Indication: Treatment of Relapsed or Refractory Hodgkin Lymphoma |
HeFi-1
For CD30 positive T-cell lymphomas
Condition: Refractory Anaplastic Large Cell Lymphoma
Clinical trials
|
Abstracts & Links
-
Distinct effects of CD30 and Fas signaling in cutaneous anaplastic lymphomas: a possible mechanism for disease progression.
J Invest Dermatol. 2000 Dec;115(6):1034-40.
PMID: 11121138 PubMed
|
Hu1D10
For 1D10 positive B-cell lymphomas
Conditions: NHL/CLL/SLL/MZL
Clinical Trials
|
Abstracts & Links
-
HLA TYPE: Recombinant IgA antibodies against HLA class II: a novel immunotherapeutic approach against B cell lymphoma Year: 2002 Abstract No: 1877
|
LMB-2 - Anti-Tac(Fv)-PE38
Recombinant immunotoxin (IL2R alpha+)
For Tac-expressing B- and T-cell NHL
Conditions: T-cell leukemia, B-cell NHL, CLL, cutaneous, peripheral and other T-cell lymphomas
Clinical Trials
|
Abstracts & Links
-
Anti-Tac Clinical Studies ClinicalTrials.gov
-
The anti-CD25 recombinant immunotoxin LMB-2 shows antitumor activity in patients with cutaneous T-cell lymphoma. Year: 2002 Abstract No: 33
|
Mono-dgA-RFB4
For CD22 positive B-cell NHL
Mono-dgA-RFB4 is a component of IMTOX 22
|
Abstracts & Links
-
Clinical Studies ClinicalTrials.gov
|
IDEC114-20
For cd80 positive B-cell lymphomas
Conditions: NHL
Clinical Trials
|
Abstracts & Links
-
Clinical study anti-cd80
-
Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma. J Biol Chem. 2002 Mar 8;277(10):7766-75. PMID: 11726649 PubMed
|
Bevacizumab
anti-VEGF - (tumor vascular endothelial growth factor)
Conditions: Aggressive NHL
Clinical Trials
|
Abstracts & Links
-
Clinical study listings for NHL ClinicalTrials.gov
-
The emerging role of angiogenesis inhibitors in hematologic malignancies. Oncology (Huntingt). 2002 May;16(5 Suppl 4):23-9.
PMID: 12102577 PubMed
|
Radiolabeled Antibodies
Radiolabeled antibodies combine Monoclonal antibodies with radioactive agents. The goal of this combination is to bring additional killing power (radiation) to the malignant cells and fewer normal cells.
|
Zevalin (IDEC-Y2B8)
Yttrium Y 90 ibritumomab tiuxetan for CD20 positive B-cell lymphomas
|
Details Approved by the FDA
|
Bexxar
Iodine-131 Anti-B1 Antibody for CD20 positive B-cell lymphomas
|
Details Under review by FDA ODAC (Aug 2002)
|
Lym-1
Iodine I 131 monoclonal antibody for CD20 positive B-cell lymphomas
Condition: Recurrent NHL
|
Abstracts & Links
-
Milestones in the development of Lym-1 therapy.
Hybridoma. 1999 Feb;18(1):1-11. Review.
PMID: 10211782 PubMed
-
Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Cancer. 1997 Dec 15;80(12 Suppl):2706-11.
PMID: 9406728 PubMed
|
Yttrium-90 Radiolabeled Humanized Anti-Tac and Calcium-DTPA
Condition: T-cell lymphoma
|
Abstracts & Links
-
Rapid and specific uptake of anti-Tac disulfide-stabilized Fv by interleukin-2 receptor-bearing tumors.
Cancer Res. 1995 Jan 15;55(2):318-23.
PMID: 7812965 PubMed
|
LR131 - Radiolabeled BLyS protein
For BLyS expressing B-cell lymphomas
|
Abstracts & Links
-
Radiolabeled BLyS protein (LR131) inhibits neoplastic B cell growth in vivo Year: 2002 Abstract No: 39
|
Other
|
Abstracts & Links
-
Anti-CD20 fusion protein shows promise in anti-NHL PRIT accessmylibrary.com
|
